Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis

Table 3 Propensity-score adjusted association of allopurinol or febuxostat with the hazard of incident dementia in patients who received allopurinol or febuxostat with a clean baseline period of 365 days*

	Hazard ratio (95% CI)	P value
Allopurinol	Ref
Febuxostat	0.79 (0.61, 1.03)	0.09
Urate-lowering therapy (ULT) dose
Allopurinol <200 mg/day	Ref
Allopurinol 200–299 mg/day	0.80 (0.64, 0.98)	0.03
Allopurinol ≥300 mg/day	0.59 (0.50, 0.71)	<0.0001
Febuxostat 40 mg/day	0.64 (0.47, 0.86)	0.003
Febuxostat 80 mg/day	0.66 (0.36, 1.19)	0.17
ULT duration
Allopurinol, 1–180 days	Ref
Allopurinol, 181–365 days	1.14 (0.86, 1.53)	0.36
Allopurinol, >1 year	1.12 (0.84, 1.49)	0.46
Febuxostat, 1–180 days	0.76 (0.53, 1.08)	0.13
Febuxostat, 181–365 days	1.09 (0.61, 1.94)	0.77
Febuxostat, >1 year	0.82 (0.44, 1.53)	0.54

Abbreviations: CI confidence interval, Ref referent category.
*Baseline period of 365 days without allopurinol or febuxostat use and without any diagnosis of dementia; A bold font indicates associations that are statistically significant with a p-value <0.05

ISSN: 1478-6362